BiotechTube

sonidegib

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Basal Cell Carcinoma

Conditions

Basal Cell Carcinoma

Trial Timeline

Mar 11, 2019 → Mar 14, 2025

NCT ID
NCT04066504

About sonidegib

sonidegib is a pre-clinical stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04066504. Target conditions include Basal Cell Carcinoma.

What happened to similar drugs?

1 of 7 similar drugs in Basal Cell Carcinoma were approved

Approved (1) Terminated (2) Active (4)
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
❌verteporfin PDTNovartisPhase 3
🔄ImiquimodViatrisPhase 3
🔄imiquimodViatrisPhase 3
🔄Patidegib Topical Gel, 2% + Patidegib Topical Gel, VehicleSol-Gel TechnologiesPhase 3
❌Patidegib Topical Gel, 2%Sol-Gel TechnologiesPhase 3
🔄BF-200 ALA + methyl-aminolevulinateBiofronteraPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04066504Pre-clinicalCompleted

Competing Products

20 competing products in Basal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split DoseVerrica PharmaceuticalsPhase 2
25
Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
43
VismodegibSun PharmaceuticalPhase 2
42
Cemiplimab Injection [Libtayo]Sun PharmaceuticalPhase 2
39
Vismodegib + SonidegibSun PharmaceuticalPre-clinical
33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
36
ABBV-8E12AbbViePre-clinical
26
Pembrolizumab + VismodegibMerckPhase 1/2
32
LDE225B + VehicleNovartisPhase 2/3
30
verteporfin PDTNovartisPhase 3
32
Vehicle + LDE225 0.25% + LDE225 0.75%NovartisPhase 2
35
LDE225NovartisPhase 2
35
LDE225 + PlaceboNovartisPhase 2
35
Buparlisib + SonidegibNovartisPhase 2
27
LDE225NovartisPre-clinical
26
LDE225 0.75% + VehicleNovartisPhase 2
27
VismodegibRochePre-clinical
26
ERIVEDGERochePhase 2
35
Placebo + VismodegibRochePhase 2
27
vismodegibRochePhase 2
35